ArticleMMWR. Morbidity and mortality weekly report2024
Use of an Additional Updated 2023-2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024.
Article in MMWR. Morbidity and mortality weekly report, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Effectiveness of Inactivated COVID-19 Vaccination Against COVID-19-Related Hospitalization and Severe Outcomes in Adults ≥80 Years During Omicron Circulation in Beijing, China: Retrospective Cohort Study.JMIR public health and surveillance · 2026Article
- Health equity-oriented design for dissemination: products and impact of rapid community translation for COVID-19 vaccine promotion.Frontiers in public health · 2026Article
- Limitations of neutralizing antibody titers in COVID-19 vaccine efficacy trials and a call for additional correlates of protection.Human vaccines & immunotherapeutics · 2025Review
- Korean red ginseng mitigates pulmonary injury and enhances antiviral immunity in a low-dose pseudo-type SARS-CoV-2 infection model.Journal of ginseng research · 2025Article
- SARS-CoV-2 Spike Protein Exacerbates Thromboembolic Cerebrovascular Complications in Humanized ACE2 Mouse Model.Translational stroke research · 2025Article
- Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults.JAMA network open · 2025Article
- Optimal Timing of Vaccination: A Narrative Review of Integrating Strategies for COVID-19, Influenza, and Respiratory Syncytial Virus.Infectious diseases and therapy · 2025Review
- Article
- Neutralizing antibody responses to three XBB protein vaccines in older adults.Signal transduction and targeted therapy · 2025Article
- Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants.Viruses · 2025Article
- Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States.Infectious diseases and therapy · 2025Article
- Article
- Adjuvant combination and antigen multimerization shape neutralizing antibody and T cell responses to a SARS-CoV-2 RBD subunit vaccine.Frontiers in immunology · 2025Article
- Politicians, power, and the people's health: US elections and state health outcomes, 2012-2024.Health affairs scholar · 2024Article
- Article
- Risk of COVID-19 in Children throughout the Pandemic and the Role of Vaccination: A Narrative Review.Vaccines · 2024Review
- Review
- Humoral and cell-mediated immune responses to COVID-19 vaccines up to 6 months post three-dose primary series in adults with inborn errors of immunity and their breakthrough infections.Frontiers in immunology · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 remains an important public health threat, despite overall decreases in COVID-19-related severe disease since the start of the COVID-19 pandemic. COVID-19-associated hospitalization rates remain higher among adults aged ≥65 years relative to rates in younger adults, adolescents, and children; during October 2023-January 2024, 67% of all COVID-19-associated hospitalizations were among persons aged ≥65 years. On September 12, 2023, CDC's Advisory Committee on Immunization Practices (ACIP) recommended updated (2023-2024 Formula) COVID-19 vaccination with a monovalent XBB.1.5-derived vaccine for all persons aged ≥6 months to protect against severe COVID-19-associated illness and death. Because SARS-CoV-2 continues to circulate throughout the year, and because of the increased risk for COVID-19-related severe illness in persons aged ≥65 years, the protection afforded by updated vaccines against JN.1 and other currently circulating variants, and the expected waning of vaccine-conferred protection against disease, on February 28, 2024, ACIP recommended all persons aged ≥65 years receive 1 additional dose of the updated (2023-2024 Formula) COVID-19 vaccine. Implementation of these recommendations is expected to enhance immunity that might have waned and decrease the risk for severe COVID-19-associated outcomes, including death, among persons aged ≥65 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.